Publications by authors named "Balazs Kanyo"
Background: Bupropion is thought to exert its antidepressive effect by blocking the dopamine transporter (DAT). The purpose of this study was to evaluate the DAT activity in depressed patients by means of 99mTc-TRODAT-1 SPECT in relation to the efficacy of bupropion treatment.
Methods: In 12 healthy controls and 16 depressed patients the baseline DAT activity was examined.
Background: In the present study D2 receptor occupancy was investigated in quetiapine treated schizophrenic patients for the detection of a relationship between the scintigraphic pattern and clinical signs and symptoms.
Material And Methods: In 10 schizophrenic patients [123I]IBZM-SPECTs were performed during the introduction of quetiapine therapy (600-800 mg/day) and during a lower maintenance dose (200-400 mg/day). The patients' clinical follow-up was continued for 1 year.
[Change of dopamine transporter activity (DAT) during the action of bupropion (in depression)].
Neuropsychopharmacol Hung
June 2004
Bupropion has an antidepressant effect through blocking the dopamine transporter. By 99mTc-TRODAT-SPECT, we measured the baseline DAT activity of depressed patients. After 3 weeks' bupropion treatment we studied the change in DAT activity, which corresponds to the occupancy of bupropion.
View Article and Find Full Text PDFUnlabelled: 99mTc-TRODAT-1 is a new, technetium based radiopharmaceutical that selectively binds to the dopamine transporters. The aim of the study was to evaluate the dopamine transporter status in movement disorders.
Methods: In eight healthy volunteers (age range 22-58 years), 28 patients with Parkinson's disease (age range 42-80 years), 10 patients with Parkinsonian syndrome (age range 51-79 years) and 13 patients with essential tremor (age range 43-71 years) were 99mTc-TRODAT-SPECT tests performed.